AI
But we do have a pretty good pipeline, although young, and results coming up for a ph2b trial in type 2 diabetes - HUGE market. It'll take years, not months .... but mgmt has indicated once they have good-to-great results with LX4211, they'll partner it out. A Big Pharma will have the cash and resources to pilot it through a ph3 and an NDA. Short term, we have LX4211 results in about 2 more weeks, and if good we should see another 10-20% move. Percentage wise not too much, because we've had a pretty good runup already, from the $1.55 area. I'd love to be wrong on the low end though!
Best regards,
Trond
Recent LXRX News
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • SBC • Nov 7, 2024 7:00 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
